Zevtera / Mabelio (ceftobiprole)

Indicaton

Hospital- and community-acquired pneumonia

Therapeutic indications

Infectious disease

Type of product

Small molecule

Table

Phase

Marketed
Partnering status

Partnered
Partner

Advanz for Europe (excl. Nordics) and Israel; Unimedic for Nordics; Hikma for MENA region, Knight Grupo Biotoscana for Latin America; Avir for Canada, CR Gosun for China, JSC Lancet for Eurasian Economic Union
Available in

Major European and several international markets

You may also be interested in

Debio 4028

Infectious diseases Debio 4028 program leverages the immunomodulatory, pro-apoptotic and virus-reactivating properties of a new generation of potent, orally available Inhibitor of Apoptosis Proteins (IAP) antagonists to cure various chronic infectious diseases. These new molecules are expected to allow the discontinuation of any antiviral treatment and eliminate the risk of clinical relapse, transmission of the infection and long-term complications.

Debio 1454/M

GI disorders

MV-003 Dysbiosis

Dysbiosis ApyraMed promotes microbiome recovery and selection of beneficial bacteria after antibiotic treatment. This results in powerful control of antibiotic-induced enteric infections and metabolic alterations.